...
首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue
【24h】

Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue

机译:与肝组织相比,大鼠夹心培养的肝细胞中药物的细胞内未结合浓度和亚细胞定位的测定

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Prediction of clinical efficacy, toxicity, and drug-drug interactions may be improved by accounting for the intracellular unbound drug concentration (Cunbound) in vitro and in vivo. Furthermore, subcellular drug distribution may aid in predicting efficacy, toxicity, and risk assessment. The present study was designed to quantify the intracellular Cunbound and subcellular localization of drugs in rat sandwich-cultured hepatocytes (SCH) compared with rat isolated perfused liver (IPL) tissue. Probe drugs with distinct mechanisms of hepatocellular uptake and accumulation were selected for investigation. Following drug treatment, SCH and IPL tissues were homogenized and fractionated by differential centrifugation to enrich for subcellular compartments. Binding in crude lysate and cytosol was determined by equilibrium dialysis; the Cunbound and intracellularto- extracellular Cunbound ratio (Kpu,u) were used to describe accumulation of unbound drug. Total accumulation (Kpobserved) in whole tissue was well predicted by the SCH model (within 2- to 3-fold) for the selected drugs. Ritonavir (Kpu,u1) was evenly distributed among cellular compartments, but highly bound, which explained the observed accumulation within liver tissue. Rosuvastatin was recovered primarily in the cytosolic fraction, but did not exhibit extensive binding, resulting in a Kpu,u 1 in liver tissue and SCH, consistent with efficient hepatic uptake. Despite extensive binding and equestration of furamidine within liver tissue, a significant portion of cellular accumulation was attributed to unbound drug (Kpu,u 16), as expected for a charged, hepatically derived metabolite. Data demonstrate the utility of SCH to predict quantitatively total tissue accumulation and elucidate mechanisms of hepatocellular drug accumulation such as active uptake versus binding/sequestration.
机译:通过考虑体外和体内的细胞内未结合药物浓度(Cunbound),可以改善临床疗效,毒性和药物相互作用的预测。此外,亚细胞药物的分布可能有助于预测疗效,毒性和风险评估。本研究旨在量化大鼠夹心培养的肝细胞(SCH)与大鼠分离的灌注肝脏(IPL)组织相比,药物在细胞内的Cunbound和亚细胞定位。选择具有不同肝细胞摄取和积累机制的探针药物进行研究。药物处理后,将SCH和IPL组织均质化,并通过差速离心分离以富集亚细胞区室。通过平衡透析确定粗裂解物和细胞质中的结合。 Cunbound和细胞内与细胞外Cunbound比率(Kpu,u)用于描述未结合药物的积累。所选药物的SCH模型可以很好地预测整个组织中的总累积量(Kpobserved)(2-3倍以内)。利托那韦(Kpu,u1)均匀分布在细胞区室中,但高度结合,这解释了观察到的肝组织内积累。瑞舒伐他汀主要在细胞溶质级分中回收,但未表现出广泛结合,导致肝组织和SCH中的Kpu,u <1,与有效的肝吸收相一致。尽管呋喃idine啶在肝组织中具有广泛的结合和吸收作用,但正如对带电荷的肝脏衍生代谢产物所期望的那样,细胞积累的很大一部分归因于未结合的药物(Kpu,u <16)。数据证明了SCH可以用于定量预测总的组织积累并阐明肝细胞药物积累的机制,例如主动摄取与结合/隔离的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号